{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:42:56Z","timestamp":1787071376552,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Small-cell lung cancer (SCLC) is a highly aggressive malignancy with a poor prognosis. 18F-fluorodeoxyglucose (FDG) positron emission tomography\/computed tomography (PET\/CT) plays a critical role in staging, as elevated FDG uptake is associated with tumor aggressiveness and metabolic activity. Although radiometabolic parameters such as maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) have been proposed as prognostic markers, existing data remain inconsistent. This study aimed to investigate the association between these parameters and disease stage and overall survival (OS) in SCLC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Patients diagnosed with lung cancer between May 2022 and June 2023 were retrospectively reviewed and divided into two groups: those with SCLC (Group 1) and those with non-SCLC (Group 2). Demographic, clinical, radiological (thoracic CT), and radiometabolic (PET\/CT) features, treatment history, staging, and mortality data (based on the national death registry) were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      A total of 111 patients (mean age: 65.2 years) were included, of whom 65 (58.6%) had SCLC. In the SCLC group, 55 (85.9%) had extensive-stage disease and 9 (14.1%) had limited-stage disease. Mean SUVmax, MTV, and TLG values were significantly higher in extensive-stage disease (12.5, 87.2, and 624.2, respectively) than in limited-stage disease (7.1, 7.0, and 37.0) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Median OS was 12.5 months. Cutoff values for poor prognosis were identified as SUVmax \u226510, MTV \u226540, and TLG \u2265170, with significantly shorter OS observed above these thresholds (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). While SUVmax alone was not an independent predictor of survival (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.05), MTV and TLG were identified as significant prognostic indicators in multivariate analysis (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>In SCLC, higher SUVmax values are associated with advanced disease stage. However, MTV and TLG may serve as more reliable independent prognostic biomarkers for survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/atm.atm_87_25","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T19:00:07Z","timestamp":1775588407000},"page":"140-146","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The impact of radiometabolic features on the stage and survival in small cell lung cancer"],"prefix":"10.4103","volume":"21","author":[{"given":"Coskun","family":"Dogan","sequence":"first","affiliation":[{"name":"Department of Pulmonology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sedanur Coskun","family":"Tok","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Karakaya","sequence":"additional","affiliation":[{"name":"Clinic of Chest Diseases, University of Health Sciences, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif Torun","family":"Parmaksiz","sequence":"additional","affiliation":[{"name":"Clinic of Chest Diseases, University of Health Sciences, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferhan","family":"Karatas","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Faculty of Medicine, Ko\u00e7 University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysenur Toks\u00f6z","family":"Yildirim","sequence":"additional","affiliation":[{"name":"Department of Pathology, Istanbul Medeniyet University, G\u00f6ztepe Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"G\u00fcng\u00f6r","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"\u0130ncealt\u0131n","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Faculty of Medicine, Istanbul Medeniyet University, G\u00f6ztepe Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacit","family":"\u0130\u00e7ten","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Faculty of Medicine, Istanbul Medeniyet University, G\u00f6ztepe Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"R2-20260706","doi-asserted-by":"crossref","first-page":"115891","DOI":"10.1016\/j.biopha.2023.115891","article-title":"Advances and challenges in the treatment of lung cancer","volume":"169","author":"Li","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"R3-20260706","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R4-20260706","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2478\/raon-2020-0054","article-title":"Neutrophil-to-lymphocyte ratio can predict outcome in extensive-stage small cell lung cancer","volume":"54","author":"Drpa","year":"2020","journal-title":"Radiol Oncol"},{"key":"R5-20260706","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R6-20260706","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.0.CO;2-Y","article-title":"The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma","volume":"83","author":"Ahuja","year":"1998","journal-title":"Cancer"},{"key":"R7-20260706","first-page":"95","article-title":"The use of FDG-PET scanning in lung cancer","volume":"53","author":"S\u00f6nmezo\u011flu","year":"2005","journal-title":"Tuberk Toraks"},{"key":"R8-20260706","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1200\/JCO.2004.11.089","article-title":"Positron emission tomography in limited-stage small-cell lung cancer: A prospective study","volume":"22","author":"Bradley","year":"2004","journal-title":"J Clin Oncol"},{"key":"R9-20260706","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fmed.2019.00336","article-title":"Impact of (18)F-FDG PET\/CT in staging patients with small cell lung cancer: A systematic review and meta-analysis","volume":"6","author":"Martucci","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"R10-20260706","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/diagnostics11020174","article-title":"Prognostic value of (18)F-FDG-PET parameters in patients with small cell lung cancer: A meta-analysis and review of current literature","volume":"11","author":"Christensen","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R11-20260706","doi-asserted-by":"crossref","first-page":"945602","DOI":"10.3389\/fmed.2022.945602","article-title":"Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose","volume":"9","author":"Zhu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R12-20260706","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.lungcan.2008.06.004","article-title":"Relationship between primary tumor fluorodeoxyglucose uptake and nodal or distant metastases at presentation in T1 stage non-small cell lung cancer","volume":"63","author":"Li","year":"2009","journal-title":"Lung Cancer"},{"key":"R13-20260706","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtcvs.2004.11.007","article-title":"The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival","volume":"130","author":"Cerfolio","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R14-20260706","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/(SICI)1097-0142(19970915)80:6<1046::AID-CNCR6>3.0.CO;2-7","article-title":"Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival","volume":"80","author":"Younes","year":"1997","journal-title":"Cancer"},{"key":"R15-20260706","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12149-009-0237-5","article-title":"Relationship between maximum standardized uptake value (SUVmax) of lung cancer and lymph node metastasis on FDG-PET","volume":"23","author":"Nambu","year":"2009","journal-title":"Ann Nucl Med"},{"key":"R16-20260706","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1158\/1078-0432.CCR-08-2258","article-title":"High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer","volume":"15","author":"Lee","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R17-20260706","doi-asserted-by":"crossref","first-page":"e2772","DOI":"10.1097\/MD.0000000000002772","article-title":"The highest metabolic activity on FDG PET is associated with overall survival in limited-stage small-cell lung cancer","volume":"95","author":"Kwon","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R18-20260706","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0300060519892419","article-title":"Prognostic value of 18F FDG PET\/CT metabolic parameters in small cell lung cancer","volume":"48","author":"Choi","year":"2020","journal-title":"J Int Med Res"},{"key":"R19-20260706","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1590\/1806-9282.20220325","article-title":"What is the effect of tumor diameter, lymph node metastases, and SUVmax value on prognosis in limited-stage small cell lung cancer?","volume":"68","author":"\u00c7imen","year":"2022","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"R20-20260706","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1470-7330-14-2","article-title":"Prognostic value of volumetric metabolic parameters measured by [18F] fluorodeoxyglucose-positron emission tomography\/computed tomography in patients with small cell lung cancer","volume":"14","author":"Park","year":"2014","journal-title":"Cancer Imaging"},{"key":"R21-20260706","first-page":"828","article-title":"Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer","volume":"39","author":"Ding","year":"2017","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"R22-20260706","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s00432-019-02848-9","article-title":"Prognostic significance of metabolic parameters measured by (18)F-FDG PET\/CT in limited-stage small-cell lung carcinoma","volume":"145","author":"Chang","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"R23-20260706","doi-asserted-by":"crossref","first-page":"27","DOI":"10.29271\/jcpsp.2023.01.27","article-title":"Total lesion glycolysis obtained by FDG PET\/CT in diagnosing solitary pulmonary nodules","volume":"33","author":"Gungor","year":"2023","journal-title":"J Coll Physicians Surg Pak"},{"key":"R24-20260706","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.lungcan.2014.09.006","article-title":"Prognostic evaluations of small size lung cancers by 18F-FDG PET\/CT and thin-section CT","volume":"86","author":"Kishimoto","year":"2014","journal-title":"Lung Cancer"},{"key":"R25-20260706","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.semnuclmed.2022.04.007","article-title":"The value of the standardized uptake value (SUV) and metabolic tumor volume (MTV) in lung cancer","volume":"52","author":"Hicks","year":"2022","journal-title":"Semin Nucl Med"},{"key":"R26-20260706","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/02184923231187279","article-title":"Accuracy of nodal staging by 18F-FDG-PET\/CT in limited disease small-cell lung cancer","volume":"31","author":"Hockmann","year":"2023","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"R27-20260706","first-page":"35","article-title":"The association of the SUVMax value measured on PET-CT with the stage and survival in nonsmall cell lung cancers","volume":"34","author":"Do\u011fan","year":"2020","journal-title":"J Izmir Chest Hosp"}],"container-title":["Annals of Thoracic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/atm.atm_87_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:45:10Z","timestamp":1787067910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/atm.atm_87_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/atm.atm_87_25","relation":{},"ISSN":["1817-1737","1998-3557"],"issn-type":[{"value":"1817-1737","type":"print"},{"value":"1998-3557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"2025-03-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}